β-lactam/β-lactamase inhibitor combinations (AAC ed.) episode artwork

EPISODE · May 7, 2021 · 46 MIN

β-lactam/β-lactamase inhibitor combinations (AAC ed.)

from Editors in Conversation · host Cesar Arias, Robert Bonomo, Pranita Tamma

The development of β-lactam/β-lactamase inhibitors seems to be expanding rapidly and promise to be the best short-term strategy against the most recalcitrant Gram-negative pathogens. In this podcast, we will discuss the current state of the art in this field. Objectives: • Discuss how the discovery of β-lactam/β-lactam inhibitors has evolved • Review the current state-of-the-art of developing of novel β-lactam/β-lactamase inhibitors • Analyze the current and future clinical applications of these drugs against major antimicrobial-resistant pathogens. Guests: Robert Bonomo, MD. Professor and Associate Chief of Staff for Academic Affairs; Director Case-VA Center for Antimicrobial Resistance and Epidemiology, Case Western Research University, School of Medicine. Past Editor of AAC Pranita Tamma, MD. MH.S. Associate Professor of Pediatrics and Director, Pediatric Antimicrobial Stewardship Program. Johns Hopkins University. Editor of AAC. Visit https://aac.asm.org to read more

Episode metadata supplied by the publisher feed · Published May 7, 2021

Embed this episode

NOW PLAYING

β-lactam/β-lactamase inhibitor combinations (AAC ed.)

0:00 46:56

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Editors in Conversation?

This episode is 46 minutes long.

When was this Editors in Conversation episode published?

This episode was published on May 7, 2021.

Can I download this Editors in Conversation episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!